This retrospective analysis of the phase III GOYA study investigated the prognostic value of baseline metabolic tumor volume parameters and maximum standardized uptake values for overall and progression-free survival in treatment-naïve diffuse large B-cell lymphoma. Baseline total metabolic tumor volume (determined for tumors >1 mL using a threshold of 1.5 times the mean liver standardized uptake value +2 standard deviations), total lesion glycolysis, and maximum standardized uptake value positron emission tomography data were dichotomized based on receiver operating characteristic analysis and divided into quartiles by baseline population distribution. Of 1,418 enrolled patients, 1,305 had a baseline positron emission tomography scan with detectable lesions. Optimal cut-offs were 366 cm3 for total metabolic tumor volume and 3,004g for total lesion glycolysis. High total metabolic tumor volume and total lesion glycolysis predicted poorer progression-free survival, with associations retained after adjustment for baseline and disease characteristics (high total metabolic tumor volume hazard ratio: 1.71 [95% CI, 1.35-2.18]; total lesion glycolysis hazard ratio: 1.46 [95% CI, 1.15-1.86]). Total metabolic tumor volume was prognostic for progression-free survival in subgroups with International Prognostic Index scores 0-2 and 3-5, and those with different cell-of-origin subtypes. Maximum standardized uptake value had no prognostic value in this setting. High total metabolic tumor volume associated with high International Prognostic Index or non-germinal center B-cell classification identified the highest-risk cohort for unfavorable prognosis. In conclusion, baseline total metabolic tumor volume and total lesion glycolysis are independent predictors of progression-free survival in patients with diffuse large B-cell lymphoma after first-line immunochemotherapy.

中文翻译：

---

GOYA 研究中，总代谢肿瘤体积作为弥漫性大 B 细胞淋巴瘤患者的生存预测因子。


这项 III 期 GOYA 研究的回顾性分析调查了基线代谢肿瘤体积参数和最大标准化摄取值对初治弥漫性大 B 细胞淋巴瘤的总体生存率和无进展生存率的预后价值。基线总代谢肿瘤体积（使用平均肝脏标准化摄取值+2标准差的1.5倍阈值确定肿瘤>1 mL）、总病变糖酵解和最大标准化摄取值正电子发射断层扫描数据根据接收者操作特征进行二分分析并按基线人口分布分为四分位数。在 1,418 名入组患者中，1,305 名患者进行了基线正电子发射断层扫描，可检测到病变。总代谢肿瘤体积的最佳临界值为 366 cm3，总病变糖酵解的最佳临界值为 3,004g。高总代谢肿瘤体积和总病变糖酵解预测较差的无进展生存期，在调整基线和疾病特征后保留相关性（高总代谢肿瘤体积风险比：1.71 [95% CI，1.35-2.18]；总病变糖酵解风险比率：1.46 [95% CI，1.15-1.86]）。在国际预后指数评分为 0-2 和 3-5 的亚组以及具有不同细胞源亚型的亚组中，总代谢肿瘤体积可预测无进展生存期。在此情况下，最大标准化摄取值没有预后价值。高总代谢肿瘤体积与高国际预后指数或非生发中心 B 细胞分类相关，确定了不良预后的最高风险人群。 总之，基线总代谢肿瘤体积和总病灶糖酵解是一线免疫化疗后弥漫性大 B 细胞淋巴瘤患者无进展生存期的独立预测因子。